Resource Summary Report

Generated by RRID on Aug 4, 2026

JMJD3 Antibody

RRID:AB_1549620
Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 3457, RRID:AB_1549620

Antibody Information

URL: http://antibodyregistry.org/AB_1549620

Proper Citation: Cell Signaling Technology Cat# 3457, RRID:AB_1549620

Target Antigen: JMJD3

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W

Antibody Name: JMJD3 Antibody

Description: This polyclonal targets JMJD3

Target Organism: h, hr, m, horse, mouse, human, mk

Antibody ID: AB_1549620

Vendor: Cell Signaling Technology

Catalog Number: 3457

Record Creation Time: 20250820T005154+0000

Record Last Update: 20250820T092405+0000

Ratings and Alerts

No rating or validation information has been found for JMJD3 Antibody.

No alerts have been found for JMJD3 Antibody.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Kuroha K, et al. (2025) Abnormal H3K27me3 underlies degenerative spermatogonial stem cells in cryptorchid testis. Development (Cambridge, England), 152(2).

Wang J, et al. (2025) NF-?B-mediated enhancement of H3K27me3 through EZH2: a mechanism to suppress pyocyanin-induced autophagy in macrophages. European journal of medical research, 30(1), 346.

Lee JH, et al. (2024) TGF-? and RAS jointly unmask primed enhancers to drive metastasis. Cell, 187(22), 6182.

Zhong Y, et al. (2023) Dexmedetomidine suppresses hippocampal astrocyte pyroptosis in cerebral hypoxic-ischemic neonatal rats by upregulating microRNA-148a-3p to inactivate the STAT/JMJD3 axis. International immunopharmacology, 121, 110440.

Hu X, et al. (2022) Epigenetic drug screen identified IOX1 as an inhibitor of Th17-mediated inflammation through targeting TET2. EBioMedicine, 86, 104333.